Want to join the conversation?
$NUVA said it agreed to buy Biotronic NeuroNetwork for $98MM in cash. Both companies' BoD unanimously approved deal. $NUVA expects transaction to immediately add to its non-GAAP EPS in 2016 and significantly add in 2017 and beyond. $NUVA sees deal to support 2016 non-GAAP operating margin guidance of 15.8% and longer-term revenue growth forecast.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.